These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22110239)

  • 1. 3D breast ultrasound: a significant predictor in breast cancer reduction under pre-operative chemotherapy.
    Warm M; Duda V; Eichler C; Harbeck N; Gossmann A; Thomas A; Hoopmann M; Ohlinger R; Breidenbach M; Kates RE
    Anticancer Res; 2011 Nov; 31(11):4039-42. PubMed ID: 22110239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Response evaluation with mammography and ultrasound].
    Junkermann H; Schmid H; Sinn HP; Wallwiener D
    Zentralbl Gynakol; 1996; 118(10):572-3. PubMed ID: 8999712
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of shear wave elastography and Ki-67 index as a novel predictive modality for the pathological response to neoadjuvant chemotherapy in patients with invasive breast cancer.
    Ma Y; Zhang S; Zang L; Li J; Li J; Kang Y; Ren W
    Eur J Cancer; 2016 Dec; 69():86-101. PubMed ID: 27821323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary systemic therapy in breast cancer patients (2007-2010)].
    Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
    Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
    Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
    Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
    von Minckwitz G; Möbus V; Schneeweiss A; Huober J; Thomssen C; Untch M; Jackisch C; Diel IJ; Elling D; Conrad B; Kreienberg R; Müller V; Lück HJ; Bauerfeind I; Clemens M; Schmidt M; Noeding S; Forstbauer H; Barinoff J; Belau A; Nekljudova V; Harbeck N; Loibl S
    J Clin Oncol; 2013 Oct; 31(28):3531-9. PubMed ID: 23980081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
    Liu ZZ; Lu ZD; Zhang HW; Yang H; Liu H; Li LF; Li WL; Cui SD
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):544-6. PubMed ID: 22093636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
    Schelling M; Avril N; Nährig J; Kuhn W; Römer W; Sattler D; Werner M; Dose J; Jänicke F; Graeff H; Schwaiger M
    J Clin Oncol; 2000 Apr; 18(8):1689-95. PubMed ID: 10764429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
    Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
    Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
    Peintinger F; Kuerer HM; Anderson K; Boughey JC; Meric-Bernstam F; Singletary SE; Hunt KK; Whitman GJ; Stephens T; Buzdar AU; Green MC; Symmans WF
    Ann Surg Oncol; 2006 Nov; 13(11):1443-9. PubMed ID: 17028770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-benefit analysis of preoperative breast MRI in patients with primary breast cancer.
    Siegmann KC; Baur A; Vogel U; Kraemer B; Hahn M; Claussen CD
    Clin Radiol; 2009 Apr; 64(4):403-13. PubMed ID: 19264186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
    Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
    Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.